[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ambiguous-lineage-leukemia-or-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ambiguous-lineage-leukemia-or-lymphoma":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100334406","phase-1-pilot-imaging-study-of-leukemia-100334406",false,"NCT03633955","Pilot Imaging Study of Leukemia","Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging","REALIZE","Inclusion Criteria:\n\n1. Aged 4 to 80 years\n2. Evidence of high-risk hematopoietic malignancy with relapsed\u002Frefractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma\n3. Karnofsky\u002FLansky score of ≥ 50\n4. Agree to use contraceptive measures during study protocol participation (when age appropriate)\n5. Patient or parent\u002Fguardian capable of providing informed consent.\n6. Ability to undergo 18F FLT imaging without sedation\n7. Bilirubin \\\u003C 2.5 mg\u002FdL, AST\u002FALT \\\u003C5x upper limit of normal, Serum creatinine \\\u003C 1.0 or 2x the upper limit of normal (whichever is higher)\n8. Pulse oximetry of \\> 90% on room air\n9. Ability to undergo 18F FLT imaging without sedation\n10. Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy).\n\nExclusion Criteria:\n\n1. Patients with uncontrolled infections\n2. Pregnancy or lactating\n3. History of prior fluorothymidine allergy or intolerance.","ALL","4 Years","80 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.",[28,29,30,31],"Acute Lymphocytic Leukemia","Acute Myeloid Leukemia","Ambiguous Lineage Leukemia or Lymphoma","Myeloma",[33],"FLT","RECRUITING","2026-04-21",{"date":37,"type":38},"2026-04-23","ACTUAL",{"date":40,"type":38},"2023-01-19",{"date":42,"type":22},"2029-04",{"name":44,"class":45},"University of Oklahoma","OTHER",3]